You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developmental Disabilities Dentistry Online

    SBC: PRAXIS, INC.            Topic: NIDCR

    DESCRIPTION (provided by applicant): Individuals with intellectual and developmental disabilities (I/DD) have more untreated caries and a higher prevalence of gingivitis and other periodontal diseases than the general population (NIDCR, 2009). In order to address this health care disparity, more dentists are needed who understand and are trained to meet the needs of this population. Few in-depth ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. High Permeance Hybrid Membranes for CO2 Separation

    SBC: ASPEN PRODUCTS GROUP INC            Topic: 09a

    The capability to efficiently remove carbon dioxide from industrial gas streams is desirable for a wide variety of applications. Carbon dioxide (CO2) is a byproduct of many industrial processes associated with the transformation of fossil fuels into usable products such as heat, electricity, and chemicals. In addition to being a greenhouse gas pollutant, the presence of carbon dioxide in chemical ...

    SBIR Phase I 2011 Department of Energy
  3. Novel serotonergic, pro-cognitive antipsychotic therapies

    SBC: Galenea Corporation            Topic: NIMH

    DESCRIPTION (provided by applicant): This application, Novel serotonergic, pro-cognitive antipsychotic therapies , is in response to PA-08-142: Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44]). Schizophrenia is a devastating brain disorder that affects approximately 0.7% of the global population. The symptoms of schizophrenia can be grouped into three major categories: posit ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a discovery platform based on microfluidics and fluorescent cell f

    SBC: NIVARTA, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The overall goal of the project is to develop discovery platform based on microfluidics and functional cell assays that is suitable for screening hundreds of proteins or small-molecule compounds simultaneously in a cost-effective and high throughput manner. The projects Specific Aims are: (1) To develop a microfluidic-based platform for high-throughput screenin ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Benzodiazepine Analogs as Novel Treatments for Catatonia

    SBC: ORGANIX CHEMISTRY SOLUTIONS LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Catatonia is a widespread and serious syndrome characterized by mutism, stupor, refusal to eat or drink, posturing, and hypokinesis, and affects a broad range of psychiatric and other patients in the US and worldwide. Untreated or poorly managed catatonic patients suffer from a wide range of ailments including bed sores, deep venous thrombi, pulmonary emboli, u ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a prototype system for assaying exocytosis from individual cells

    SBC: EXOCYTRONICS, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Cells secrete hormones and neurotransmitter via exocytosis. Understanding how exocytosis is regulated and how pharmaceuticals and toxins inhibit exocytosis is of broad medical significance. The overall goal of this SBIRproject is to use microfabrication technology to develop a robust and easy-to-use prototype device that can assay release of transmitter from in ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Amelioration of Claustrophobia and Disruptive Patient Motion in MR Imaging

    SBC: HYPNALGESICS, LLC            Topic: NCCAM

    DESCRIPTION (provided by applicant): Claustrophobia and disruptive patient motion are common impediments to MRI examination, but they may be prevented or ameliorated with a non-pharmacologic behavioral intervention administered by trained staff. The potential benefits of such an intervention are highly significant, considering that the alternatives are to cancel the study or administer sedation. I ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. In vitro tools for preclinical analysis of cognitive therapies for schizophrenia

    SBC: Galenea Corporation            Topic: NIMH

    DESCRIPTION (provided by applicant): Schizophrenia is a debilitating disease that afflicts 1% of the US population. Symptoms of schizophrenia are classified into three categories: positive (delusions and hallucinations), negative (flattened affect, socialisolation) and cognitive (impaired attention, executive function, working memory). Existing antipsychotics, while effective at treating the posit ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Tr1-Specific Tolerance: a Novel Treatment of Multiple Sclerosis

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): We are developing a novel immunomodulatory therapy, hR-411, to treat relapsing-remitting multiple sclerosis (RRMS). hR-411 restores regulatory T-cell balance by redirecting pathogenic Th1/Th17 cells into tolerance-inducing Tr1 cells. hR-411 is formed from the fusion of human Ig-Fc and CXCL11, a CXCR3-binding ligand that has been recently identified as a cou ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. A Rapid Point-of-care Diagnostic for Neisseria gonorrhoeae STDs

    SBC: NetBio, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Improved diagnosis of Neisseria gonorrhoeae (GC) infections represents a critical unmet medical need. The CDC estimates that approximately 700,000 people are infected by GC annually, with approximately half of these cases reported. The clinical spectrum of GC infection includes urethritis and cervicitis, pelvic inflammatory disease (PID), and disseminated disea ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government